<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979966</url>
  </required_header>
  <id_info>
    <org_study_id>C-II-006 / 2009-010143-13</org_study_id>
    <nct_id>NCT00979966</nct_id>
  </id_info>
  <brief_title>Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib</brief_title>
  <official_title>Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, open-label, randomized multicenter phase-II study to evaluate
      progression free survival (PFS) in patients with locally advanced or metastatic non-clear
      cell renal cell cancer (ncc-RCC) receiving Temsirolimus in comparison to Sunitinib.

      In most clinical trials in renal cell carcinoma (RCC), clear cell RCC have been included
      exclusively. There are only some limited data on the efficacy of Temsirolimus or Sunitinib in
      ncc-RCC showing interesting response rates for both agents. However, randomized clinical
      trials in this specific patient population have not yet been performed.

      In the proposed study a comparison Temsirolimus and Sunitinib is scheduled in first line
      therapy of ncc-RCC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>7-11 months expected</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>7-11 months expected</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety assessed using CTCAE v3.0 and safety assessed according to reported SAEs</measure>
    <time_frame>8-12 months (treatment duration + 1 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year progression free survival rate (1YPFSR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>will be evaluated in 2013</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Non-clear Cell Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25 mg intravenously, once weekly infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg oral once daily for 4 weeks, followed by 2 weeks rest.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males and females: ≥18 years of age.

          2. Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all
             subtypes. Patients must have advanced non-clear cell of one of the following subtypes:
             papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma
             (RMC), or unclassified.

          3. Patients with measurable disease (at least one uni-dimensionally measurable target
             lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: ≥ 1 measurable
             lesion that has not been irradiated.

          4. PS 0-2 ECOG

          5. Signed written informed consent.

          6. White blood cell count (WBC) ≥4x10*9/L with neutrophils ≥1.5 x 10*9/L, platelet count
             ≥100x10*9/L, hemoglobin ≥9 g/dL.]

          7. Total bilirubin &lt;2 x upper limit of normal.

          8. AST and ALT &lt;2.5 x upper limit of normal, or &lt;5 x upper limit of normal in case of
             liver metastases.

          9. Serum creatinine &lt;2.0 x upper limit of normal.

         10. Normal ECG without QT prolongation (QTc &lt; 450msec).

         11. Adequate cardiac function (left ventricular ejection fraction &gt; 40% as assessed by
             ECHO.

        Exclusion Criteria:

          1. Predominant clear-cell RCC

          2. Resectability or other curative options

          3. Any investigational drug within the 30 days before inclusion.

          4. Prior systemic treatment for their RCC.

          5. Known or suspected allergy or hypersensitivity reaction to any of the components of
             study treatments.

          6. Radiotherapy within the last 4 weeks.

          7. Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.

          8. Men or women of child-bearing potential who are sexually active and unwilling to use a
             medically acceptable method of contraception during the trial.

          9. Clinically symptomatic brain or meningeal metastasis. (known or suspected)

         10. Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin).

         11. History of any of the following cardiac events within the past 6 months:

               -  myocardial infarction (including severe/unstable angina),

               -  coronary/peripheral artery bypass graft,

               -  congestive heart failure (CHF),

               -  cerebrovascular accident,

               -  transient ischemic attack,

               -  pulmonary embolism.

         12. No hemorrhage ≥ grade 3 within the past 4 weeks

         13. Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90
             mm Hg despite the use of ≥3 anti-hypertensive drugs

         14. History of relevant pulmonary hypertension or interstitial lung disease.

         15. Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or
             chronic diarrhea

         16. Previous malignancy (other than renal cancer cancer) in the last 5 years except basal
             cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder
             tumor [Ta, Tis and T1].

         17. History of organ allograft

         18. Significant disease which, in the investigator`s opinion would exclude the patient
             from the study

         19. Patients with seizure and epileptic disorder or other conditions requiring medication
             (such as phenytoin, carbamazepin, phenobarbital)

         20. Patients under strong inducers or inhibitors to CYP Isoenzymes

         21. Patients with hypersensitivity to the antihistamine or patients who cannot receive the
             antihistamine for other medical reasons

         22. Patients requiring long-term cortisone therapy

         23. Patients requiring oral anticoagulation treatment, such as marcoumar. (Anticoagulation
             treatment with heparin or low molecular weight heparin [LMWH] is allowed provided that
             close monitoring is performed).

         24. Surgery within at least 2 weeks prior to randomization

         25. HIV seropositivity.

         26. Abnormal pulmonary function (DLCO &lt; 50%). [Pulmonary function tests need only to be
             performed if abnormal pulmonary function present in medical history].

         27. Poorly controlled diabetes mellitus.

         28. Liver cirrhosis, chronic hepatitis

         29. Legal incapacity or limited legal capacity

         30. Known alcohol or drug abuse.

         31. Medical or psychological conditions that would not permit the patient to complete the
             study or sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Bonn gGmbH - Johanniter-Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK-SH Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin,</name>
      <address>
        <city>Viersen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG - Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cesar.or.at/</url>
    <description>German description on the CESAR homepage</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

